GlassScriptPhysician profile
Melissa R Freese
NPI 1437549870
$7,157.01
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,113 · 2022: $2,819 · 2023: $3,162 · 2024: $63.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,225.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,898.65 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $804.70 | 2021-2024 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $784.55 | 2021-2023 | Entyvio, Gattex |
| Janssen Biotech, INC. | $732.74 | 2021-2023 | Stelara |
| Celgene Corporation | $532.97 | 2021-2023 | Zeposia |
| Amgen INC. | $481.78 | 2021-2023 | Avsola, Amjevita |
| Nestle Healthcare Nutrition INC. | $455.78 | 2021-2023 | |
| Organon LLC | $256.26 | 2022-2023 | Renflexis, Hadlima |
| Intercept Pharmaceuticals, INC. | $226.94 | 2022-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $206.34 | 2021-2023 | Dificid, Zinplava |
| Regeneron Healthcare Solutions, INC. | $143.83 | 2022-2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $141.46 | 2021-2023 | Linzess |
| Genzyme Corporation | $104.66 | 2022-2023 | |
| Qol Medical, LLC | $71.72 | 2021-2023 | Sucraid |
| Fresenius Kabi USA, LLC | $55.05 | 2023 | Idacio, Smoflipid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $50.12 | 2023 | Rebyota |
| Glaxosmithkline, LLC. | $38.72 | 2022 | |
| Pfizer INC. | $31.79 | 2022 | |
| Daiichi Sankyo INC. | $30.61 | 2022-2023 | Injectafer |
| Ardelyx, INC. | $29.34 | 2022 | |
| Pharmacosmos Therapeutics INC. | $24.76 | 2022 | |
| Dynavax Technologies Corporation | $22.78 | 2021 | |
| Lilly USA, LLC | $18.44 | 2023 | |
| Alfasigma USA, INC. | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Freese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.